$BE Balance Sheet | Understand Stock

$BE

$218.44 +$14.52 (7.12%) Live

$BE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD; shares in millions, except per-share amounts

	Q3 FY2026 As of Sep 30, 2026	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021
Assets
Current assets:
Cash and cash equivalents
Restricted cash
Accounts receivable, less allowance for credit losses of $2,998 and $460 as of September 30, 2026 and December 31, 2025, respectively
Contract assets
Inventories
Deferred cost of revenue, current
Customer financing receivable
Loan commitment asset
Customer consideration asset
Prepaid expenses and other current assets
Total current assets

Property, plant and equipment, net
Investments in unconsolidated affiliates
Operating lease right-of-use assets
Customer financing receivable
Restricted cash
Contract assets
Deferred cost of revenue
Goodwill
Loan commitment asset
Customer consideration asset
Other long-term assets
Total assets

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
Accrued warranty
Accrued expenses and other current liabilities
Deferred revenue and customer deposits
Operating lease liabilities
Financing obligations
Recourse debt
Non-recourse debt
Series B redeemable convertible preferred stock
Total current liabilities

Deferred revenue and customer deposits
Operating lease liabilities
Financing obligations
Recourse debt
Non-recourse debt
Deferred profit in transactions with unconsolidated affiliates
Other long-term liabilities
Total liabilities
Redeemable convertible preferred stock, Series A: 10,000,000 shares authorized; no shares and 10,000,000 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively.
Redeemable convertible preferred stock, Series B: 13,491,701 shares and no shares authorized, and 13,491,701 shares and no shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively
Stockholders’ equity:
Common stock: 0.0001 par value; 600,000,000 shares authorized, and 295,537,217 shares and 280,045,459 shares issued and outstanding, at September 30, 2026 and December 31, 2025, respectively14
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders’ equity attributable to common stockholders
Noncontrolling interest
Total stockholders’ equity
Total liabilities and stockholders’ equity

Common stock, par value (in dollars per share)
Common stock, authorized (in shares)

Comments